Mitral Valve Prolapse

• Connective tissue abnormalities and leaflet degeneration: The fundamental defect in MVP involves myxomatous degeneration of mitral leaflet tissue, characterized by abnormal accumulation of glycosaminoglycans (particularly dermatan sulfate and hyaluronic acid) within the spongiosa layer, leading to leaflet thickening, increased compliance, and loss of structural integrity. This accumulation results from either primary genetic defects in extracellular matrix proteins (including fibrillin-1, collagen, or elastic fiber components) or secondary dysregulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). At the cellular level, valve interstitial cells become activated and produce excessive proteoglycans, disrupting the normal laminar architecture of the valve leaflets. The thickened, redundant leaflets become increasingly lax and prone to prolapse, particularly under conditions of reduced left ventricular afterload or increased contractility. This connective tissue disorder explains the association of MVP with heritable connective tissue diseases including Marfan syndrome (fibrillin-1 mutations), Ehlers-Danlos syndrome, and osteogenesis imperfecta, where primary collagen or elastic fiber defects predispose to mitral leaflet degeneration.

• Geometric and hemodynamic alterations affecting leaflet coaptation: During systole, the prolapsed leaflets fail to maintain proper geometric alignment at the mitral annular plane due to abnormal leaflet elongation (>25 mm in some cases) and annular dilation. The prolapse mechanism involves sudden superior billowing of leaflets, typically occurring at the mid-to-late portion of systole as ventricular pressure exceeds atrial pressure; this abrupt displacement generates the characteristic midsystolic click, which represents the sudden tenting and maximal stress on the elongated chordae tendineae. The degree of prolapse directly correlates with the balance between leaflet length and annular circumference—as the left ventricle contracts and volume decreases, the ratio of leaflet length to annular perimeter increases, precipitating prolapse. Reduced left ventricular afterload (such as occurs with standing, Valsalva maneuver, or amyl nitrite inhalation) decreases left ventricular cavity size, advancing the timing and magnitude of prolapse earlier in systole, which explains why MVP murmurs change with postural maneuvers. Conversely, increased afterload (squatting, handgrip, or vasoconstrictors) increases left ventricular volume, delaying and reducing prolapse. This exquisite sensitivity to loading conditions produces the characteristic dynamic nature of MVP's clinical findings on auscultation.

• Arrhythmogenic substrate and neural dysfunction: Beyond structural valve pathology, MVP generates arrhythmias through multiple mechanisms including mechanoelectrical feedback, wherein the abnormal leaflet motion and regional stress on papillary muscles and adjacent endocardium create areas of electrical heterogeneity and increased automaticity. Stretch-sensitive ion channels (mechanotransducers) in myocardial and valve tissue become activated by the abnormal mechanical deformation, leading to localized calcium handling abnormalities and generation of ectopic foci, particularly at the junction between the prolapsing leaflet and left ventricular wall. Furthermore, many MVP patients demonstrate autonomic nervous system dysfunction, including increased sympathetic tone and abnormal parasympathetic regulation, mediated through enhanced susceptibility to catecholamine effects and altered baroreceptor responsiveness. Neuroimaging and autonomic testing in symptomatic MVP patients reveals evidence of abnormal central autonomic regulation and heightened adrenergic sensitivity, which may predispose to both palpitations and syncope. The combination of structural arrhythmogenic substrate (mechanoelectrical coupling) and functional autonomic dysregulation explains why symptomatic MVP patients frequently experience palpitations and syncope out of proportion to objective electrophysiologic findings.

• Secondary mitral regurgitation and hemodynamic consequences: As prolapse progresses, the inability of elongated leaflets to coappt completely during systole results in functional mitral regurgitation (MR), allowing retrograde flow into the left atrium. The severity of MR correlates with the degree of leaflet redundancy and prolapse extent; initially MR may be trivial or mild, but progressive degenerative changes and chordal rupture can lead to hemodynamically significant MR requiring surgical intervention. Left atrial volume overload from MR subsequently dilates the mitral annulus, creating a vicious cycle of increasing prolapse and worsening regurgitation. Over decades, chronic volume overload on the left atrium and left ventricle predisposes to atrial fibrillation and eventual ventricular dilatation with systolic dysfunction, though this long-term progression occurs in only a minority of MVP patients.

• Primary MVP (classical myxomatous MVP): This represents the most common form (>80% of MVP cases), characterized by idiopathic myxomatous degeneration without association with recognized systemic disease. Genetic factors play a central role, with autosomal dominant inheritance documented in familial clusters; multiple loci have been identified (MMVP1, MMVP2, MMVP3) with incomplete penetrance and variable expressivity. Mutations in genes encoding structural proteins (FBN1, COL1A1, COL3A1) directly cause myxomatous changes; additional genetic variations affecting cell signaling pathways and extracellular matrix regulation increase susceptibility. Female predominance (2:1 ratio) suggests possible hormonal influences on matrix degeneration, though exact mechanisms remain incompletely elucidated. The prevalence increases with age, particularly over age 50, reflecting progressive degenerative changes in the valve apparatus over time.

• Secondary MVP associated with Marfan syndrome: Patients with Marfan syndrome (FBN1 mutations affecting fibrillin-1) show MVP in 60-80% of cases, with more severe leaflet degeneration, earlier progression to hemodynamically significant MR, and greater risk of arrhythmias and sudden cardiac death. The fibrillin-1 defect directly impairs elastic fiber architecture in valve tissue, explaining the accelerated myxomatous degeneration and higher complication rate compared to primary MVP. Marfan patients require more aggressive surveillance with serial echocardiography and consideration of beta-blockers or losartan to slow aortic root dilatation, which frequently accompanies mitral pathology in this syndrome.

• Secondary MVP with other connective tissue disorders: Ehlers-Danlos syndrome (particularly classical and vascular types, due to COL1A1/COL3A1 mutations), osteogenesis imperfecta, and pseudoxanthoma elasticum all predispose to MVP through primary collagen or elastic fiber defects. These patients manifest MVP earlier in life, with more severe degenerative changes and higher complication rates including spontaneous chordal rupture and acute severe MR.

• MVP associated with other cardiac conditions: Patients with atrial septal defect (ASD) show increased MVP prevalence (10-30%), likely due to altered left ventricular geometry and hemodynamics; similarly, hypertrophic cardiomyopathy (HCM) frequently coexists with MVP due to shared abnormalities in valve-septal geometry. Wolff-Parkinson-White (WPW) syndrome demonstrates higher MVP prevalence than the general population, suggesting common developmental abnormalities in cardiac tissue.

• Risk factors and modifying conditions: Conditions causing reduced left ventricular volume or afterload predispose to symptomatic MVP manifestations, including hyperthyroidism, anemia, dehydration, and chronic obstructive pulmonary disease (COPD) with right heart strain. Sympathomimetic drugs (decongestants, stimulants) and stimulant abuse (cocaine, amphetamines) exacerbate MVP-related palpitations through catecholamine sensitization of the arrhythmogenic substrate. High caffeine intake similarly worsens symptoms through increased automaticity.

• Palpitations (most common symptomatic complaint, occurring in 40-50% of symptomatic patients): Patients experience awareness of irregular or forceful heartbeats, typically described as "skipping," "racing," or "fluttering" sensations. The pathophysiologic basis involves mechanoelectrical feedback from abnormal leaflet motion generating premature ventricular and atrial contractions (ectopic foci), combined with autonomic dysregulation and heightened catecholamine sensitivity. Palpitations frequently occur in clusters, last seconds to minutes, and may be triggered by emotional stress, caffeine, or physical exertion. Importantly, objective arrhythmias on monitoring may not correlate with subjective palpitation symptoms, as many symptomatic MVP patients show only occasional premature beats while asymptomatic patients may demonstrate frequent arrhythmias, indicating that symptom perception involves autonomic and psychological factors beyond simple arrhythmia burden.

• Syncope and presyncope (occurring in 5-15% of symptomatic MVP patients): Patients experience sudden loss of consciousness or near-syncope, typically without prodrome or with minimal warning. Vasovagal syncope represents the most common mechanism, with activation of cardiac mechanoreceptors during acute mitral regurgitation triggering a Bezold-Jarisch reflex characterized by sudden vasodilation and bradycardia leading to profound hypotension. This mechanism is distinct from syncope due to malignant arrhythmias (though these also occur), and occurs more frequently in symptomatic MVP patients than in the general population. Syncope may be positional (supine to upright) or exertional, and patients typically recover fully within seconds to minutes. Life-threatening arrhythmias (ventricular fibrillation) causing syncope are rare but constitute the most serious MVP-related complication.

• Chest pain or chest discomfort (30-50% of symptomatic patients): MVP patients commonly report anterior chest discomfort, often atypical in character, lacking clear relationship to exertion, and sometimes resistant to nitrates. The pain is typically pleuritic or musculoskeletal in quality, located at the left anterior chest, and may radiate to the arm or back. Proposed mechanisms include papillary muscle ischemia from abnormal traction and stress on papillary muscles, mechanical irritation of parietal pleura by prolapsing leaflets, and enhanced pain perception related to autonomic dysregulation and increased sympathetic tone. Notably, coronary angiography and cardiac imaging are typically normal, helping distinguish MVP-related chest pain from ischemic etiology. The clinical challenge involves distinguishing MVP-related chest pain from acute coronary syndrome, though the latter should always be excluded through appropriate stress testing or coronary imaging in patients with typical anginal features or risk factors.

• Dyspnea and fatigue (10-20% of symptomatic patients): These nonspecific symptoms occur primarily in MVP patients with hemodynamically significant mitral regurgitation, wherein pulmonary venous congestion develops from elevated left atrial pressure. Dyspnea may be exertional or orthopneic, and reflects the degree of MR severity and secondary left atrial/left ventricular dilatation.

• Physical examination findings:
• Midsystolic click: The pathognomonic finding in MVP, occurring at the moment of maximal leaflet prolapse as the valve tents upward suddenly. The click represents the abrupt tensioning of elongated chordae tendineae and occurs at mid-to-late systole, distinguishable from the opening snap of mitral stenosis (which occurs early in diastole) and from aortic ejection click (which occurs early in systole at the left sternal border). The timing of the click varies with loading conditions: standing or Valsalva maneuver moves the click earlier (closer to S2) by reducing left ventricular volume, while squatting or handgrip moves the click later (away from S2) by increasing left ventricular volume. This dynamic behavior represents the most useful clinical finding for MVP diagnosis at the bedside.
• Late systolic murmur: When mitral regurgitation accompanies MVP, a high-pitched, crescendo holosystolic (or late systolic) murmur appears at the apex, radiating to the axilla. The late systolic pattern occurs because regurgitation develops only after the prolapse occurs in mid-to-late systole; a pansystolic (holosystolic) murmur suggests more severe MR with earlier onset of valve incompetence. The murmur duration and intensity also vary with loading conditions: Valsalva and standing increase murmur duration and intensity (more prolapse → more regurgitation), while squatting and handgrip reduce these findings.
• Normal S2 with possible S3 gallop: In uncomplicated MVP, S2 remains normally split. If hemodynamically significant MR develops with left ventricular dilatation, a third heart sound (S3) may appear, indicating elevated left ventricular filling pressures.

• Important clinical variants:
• Asymptomatic MVP: The majority of MVP patients (75%) remain completely asymptomatic throughout life, identified only incidentally on echocardiography during evaluation for murmur or unrelated cardiac conditions. These patients have excellent long-term prognosis and require only reassurance and periodic surveillance.
• Severe symptomatic MVP with syncope: A small but important subgroup experiences recurrent syncope or presyncope; these patients warrant comprehensive electrophysiologic evaluation, Holter or event monitoring to detect serious arrhythmias, and possibly implantable cardioverter-defibrillator (ICD) placement if malignant arrhythmias are documented.
• Progressive hemodynamically significant MR: Some MVP patients develop worsening mitral regurgitation over years to decades, eventually requiring surgical repair or replacement; this progression is more common in men, in patients with marked leaflet thickening on echocardiography (>5 mm), and in those with connective tissue disorders.

• Clinical history and physical examination: Initial assessment focuses on identifying classic auscultatory findings (midsystolic click ± late systolic murmur) on careful cardiac auscultation, particularly noting the dynamic behavior of findings with postural maneuvers. The midsystolic click is the most sensitive finding (68% of MVP patients), while the combination of click + murmur is highly specific (nearly 100%). Historical features supporting MVP include palpitations with exertion or emotional stress, syncope or presyncope without prodrome, atypical chest pain, and family history of MVP or connective tissue disorders. Inquire about associated conditions (Marfan syndrome features, EDS symptoms) and medication/substance use affecting catecholamine sensitivity.

• Echocardiography (transthoracic, TTE) - gold standard diagnostic test: Echocardiography provides definitive diagnosis and remains the single most important diagnostic modality. The diagnostic criterion for MVP requires ≥2 mm superior displacement of the mitral leaflet (or leaflets) above the mitral annular plane in the parasternal long-axis view during mid-to-late systole. Importantly, the mitral annulus should be identified as the reference plane by tracing the hinge points (bases of leaflets where they insert into annulus

Asymptomatic MVP with no or mild MR (the majority)

• Reassurance and surveillance: The ACC/AHA 2020 Valvular Heart Disease Guideline recommends no drug therapy for asymptomatic MVP with trivial/mild regurgitation; periodic clinical follow-up with echocardiography at intervals dictated by MR severity, leaflet thickening, and LV size. Encourage normal activity and adequate hydration, since hypovolemia shrinks LV cavity size and worsens prolapse.
• Trigger avoidance: caffeine, decongestants, and stimulants (cocaine, amphetamines) amplify the catecholamine-sensitive arrhythmogenic substrate.

Symptomatic palpitations, atypical chest pain, or anxiety

• Beta blockers (e.g., metoprolol): first-line; blunt adrenergic drive, slow heart rate, and increase LV end-diastolic volume, which mechanically delays and reduces prolapse. Ambulatory rhythm monitoring should precede escalation so therapy targets documented ectopy.
• Escalation: for high-burden or symptomatic PVCs/VT despite beta blockade, antiarrhythmic therapy or catheter ablation of papillary muscle/fascicular foci per electrophysiology referral; ICD per ACC/AHA–HRS secondary-prevention indications after aborted cardiac arrest or sustained VT.

Progressive mitral regurgitation

• Acute severe MR from chordal rupture is a surgical emergency — stabilize with afterload reduction (IV nitroprusside if normotensive) ± intra-aortic balloon pump as a bridge to urgent operation.
• Chronic severe primary MR: the ACC/AHA 2020 guideline gives a Class 1 recommendation for mitral surgery when symptoms develop, and in asymptomatic patients when LVEF ≤60% or LV end-systolic dimension ≥40 mm; new atrial fibrillation or pulmonary hypertension favors earlier intervention.
• Repair over replacement: degenerative MVP is the ideal repair substrate; refer to a Comprehensive Valve Center with high repair rates and low operative mortality.
• Transcatheter edge-to-edge repair: reserved for severely symptomatic (NYHA III–IV) patients with high or prohibitive surgical risk, favorable valve anatomy, and reasonable life expectancy (Class 2a).

Contraindicated / not indicated

• Infective endocarditis antibiotic prophylaxis: not recommended for MVP by the AHA — prophylaxis applies only to prosthetic valves, prior endocarditis, certain congenital lesions, and transplant valvulopathy.
• Vasodilators in asymptomatic normotensive primary MR: no proven benefit.
• Routine activity restriction for uncomplicated MVP is unwarranted.

Disease-related

• Progressive severe mitral regurgitation: leaflet redundancy plus annular dilation creates a self-perpetuating cycle of worsening coaptation failure. Signaled by conversion of a late systolic murmur to a holosystolic murmur, an S3, and rising LV/LA dimensions on serial echocardiography. MVP is the leading cause of primary (degenerative) MR requiring surgery in the United States.
• Chordal rupture with acute severe MR — emergency: sudden flail leaflet produces abrupt pulmonary edema with a hypotensive, tachypneic patient; the murmur may be soft or absent because LA and LV pressures rapidly equalize. Requires urgent echocardiography and surgical referral.
• Infective endocarditis: turbulent regurgitant jet damages the atrial surface of the leaflet, creating a nidus. Suspect with fever, new/changed murmur, and embolic phenomena; blood cultures plus echocardiography per the modified Duke criteria.
• Atrial fibrillation and thromboembolic stroke: chronic LA volume overload and stretch. Anticoagulation is decided by CHA₂DS₂-VASc; MVP-associated AF is non-valvular, so DOACs are acceptable — mechanical prostheses and rheumatic mitral stenosis are the warfarin-only exceptions.
• Ventricular arrhythmia and sudden cardiac death — emergency: the arrhythmic MVP phenotype (bileaflet prolapse, mitral annular disjunction, inferolateral T-wave inversions, polymorphic/bidirectional PVCs, papillary-muscle late gadolinium enhancement on cardiac MRI) reflects traction-induced myocardial fibrosis. Presents as unexplained syncope or arrest in ventricular fibrillation / pulseless VT.
• Heart failure: late consequence of chronic volume overload with eccentric LV remodeling.

Treatment-related

• Beta blockers: fatigue, bradycardia, bronchospasm; abrupt withdrawal causes rebound tachycardia.
• Mitral repair: systolic anterior motion of the anterior leaflet with LV outflow obstruction, residual/recurrent MR, or iatrogenic mitral stenosis; new murmur or hypotension post-op should prompt transesophageal echocardiography.
• Prosthetic replacement: valve thrombosis, paravalvular leak with intravascular hemolysis (schistocytes, elevated LDH, low haptoglobin), prosthetic endocarditis, and anticoagulation-related bleeding.
• Transcatheter edge-to-edge repair: residual MR, iatrogenic mitral gradient, device detachment.

• The murmur maneuver rule: Standing and Valsalva (↓ preload, smaller LV) move the midsystolic click earlier and lengthen the murmur. Handgrip and squatting (↑ preload/afterload) delay the click and shorten the murmur, though murmur intensity may actually increase because higher afterload raises regurgitant volume — as with any MR. Nearly every MVP stem hinges on this.
• The classic distractor: standing/Valsalva also increases the murmur of hypertrophic cardiomyopathy — but HCM has no midsystolic click, and its murmur is a harsh left sternal border crescendo–decrescendo, not an apical late systolic murmur radiating to the axilla. The reliable discriminator is that handgrip softens the HCM murmur (and augments MR/AR/VSD), and only MVP has a midsystolic click.
• Single best next step for a click ± late systolic murmur: transthoracic echocardiography — diagnostic criterion is ≥2 mm systolic leaflet displacement above the annulus in the parasternal long-axis view.
• The association examiners love: Marfan syndrome (fibrillin-1) — tall, arachnodactyly, ectopia lentis, aortic root dilation; also Ehlers-Danlos and osteogenesis imperfecta. MVP in a young tall patient = screen for aortopathy.
• No endocarditis prophylaxis: the AHA does not recommend antibiotics before dental work for MVP, even with regurgitation. This is a favorite trap answer.
• Murmur character predicts severity: a late systolic murmur suggests mild–moderate MR; a holosystolic murmur means earlier coaptation failure and more severe MR. A flail leaflet with sudden pulmonary edema and a soft or absent murmur = chordal rupture, an emergency.
• Arrhythmic MVP: bileaflet prolapse + mitral annular disjunction + inferolateral T-wave inversions + polymorphic PVCs identifies the rare patient at risk for ventricular fibrillation / pulseless VT and sudden death; cardiac MRI shows papillary-muscle fibrosis.
• MVP is the most common cause of primary MR needing surgery in the US, and repair beats replacement for degenerative disease (ACC/AHA 2020).